NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Fantastic stuff Flipper! Regardless of the relevance to the DCVax-L trial, this information and the spirit of the presentations is tremendously encouraging for the future of immunotherapies and other cancer treatments.

Possibly automated cancer subgroup detection via automated image analysis. Possibly going on right now in post data analysis in the DCVax-L trial... including distinguishing real from pseudo-progression... I assume that is what you are suggesting.

Another related benefit for DCVax-L could be the following: I have been concerned about efficacy in the Mesenchymal subgroup because I have not heard anybody say that the subgroup can be identified in time to select DCVax-L prior to surgery. That would seem to be a logistical problem to me. If so, NWBO might need to get approval for the entire GBM population, which is more difficult. But this presentation suggests that there may be a non-invasive way to identify such subgroups before surgery using "Radiomics"; if not now, then possibly in the near future. This might influence the FDA to allow approval for that subgroup even though the logistics might initially be more burdensome than the FDA would like.